0JS Stock Overview
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis retailer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MedMen Enterprises Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0072 |
| 52 Week High | CA$0.032 |
| 52 Week Low | CA$0.0054 |
| Beta | 1.42 |
| 1 Month Change | 0% |
| 3 Month Change | 30.91% |
| 1 Year Change | -16.28% |
| 3 Year Change | -97.67% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JS | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.3% | -1.5% |
| 1Y | -16.3% | -30.8% | 0.9% |
Return vs Industry: 0JS exceeded the German Pharmaceuticals industry which returned -31.5% over the past year.
Return vs Market: 0JS underperformed the German Market which returned 4.2% over the past year.
Price Volatility
| 0JS volatility | |
|---|---|
| 0JS Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0JS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0JS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 428 | n/a | www.medmen.com |
MedMen Enterprises Inc., together with its subsidiaries, operates as a cannabis retailer in the United States. The company provides products under the MedMen Red and LuxLyte brand names. As of June 25, 2022, it operated 19 stores in California, Nevada, Illinois, Arizona, and Massachusetts.
MedMen Enterprises Inc. Fundamentals Summary
| 0JS fundamental statistics | |
|---|---|
| Market cap | €16.17m |
| Earnings (TTM) | -€132.25m |
| Revenue (TTM) | €110.85m |
0.1x
P/S Ratio-0.1x
P/E RatioIs 0JS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JS income statement (TTM) | |
|---|---|
| Revenue | US$120.12m |
| Cost of Revenue | US$63.44m |
| Gross Profit | US$56.68m |
| Other Expenses | US$199.99m |
| Earnings | -US$143.31m |
Last Reported Earnings
Mar 25, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.094 |
| Gross Margin | 47.18% |
| Net Profit Margin | -119.30% |
| Debt/Equity Ratio | -82.3% |
How did 0JS perform over the long term?
See historical performance and comparison